Targeting BCL-2 as a Therapeutic Strategy for Primary p210BCR-ABL1-positive B-ALL Cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting BCL-2 as a Therapeutic Strategy for Primary p210BCR-ABL1-positive B-ALL Cells

Published:2020 Issue:2 Volume:34 Page:511-516
ISSN:0258-851X
Container-title:In Vivo
language:en
Short-container-title:In Vivo

Author:

MASSIMINO MICHELE,TIRRÒ ELENA,STELLA STEFANIA,PENNISI MARIA STELLA,VITALE SILVIA RITA,PUMA ADRIANA,ROMANO CHIARA,DI GREGORIO SANDRA,ROMEO MARIA ANNA,DI RAIMONDO FRANCESCO,MANZELLA LIVIA

Publisher

Anticancer Research USA Inc.

Subject

Pharmacology,General Biochemistry, Genetics and Molecular Biology,Cancer Research

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging biomarkers and potential therapeutics of the BCL-2 protein family: the apoptotic and anti-apoptotic context;Egyptian Journal of Medical Human Genetics;2024-01-27

2. Synergistic Effect of Venetoclax and Bendamustine in Early T-cell Precursor Acute Lymphoblastic Leukemia;In Vivo;2024

3. Combinatorial fedratinib and venetoclax treatment is effective on human B cell acute lymphoblastic leukemia with high Flt3 expression;2023-06-09

4. In the Pipeline—Emerging Therapy for ALL;Pathogenesis and Treatment of Leukemia;2023

5. The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia;International Journal of Molecular Sciences;2022-09-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP